Ipamorelin

Ipamorelin: The Selective GH Secretagogue — No Cortisol, No Prolactin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) growth hormone secretagogue that selectively binds the ghrelin receptor (GHS-R1a) on anterior pituitary somatotrophs. This receptor activation triggers pulsatile growth hormone (GH) secretion with comparatively little activation of ACTH/cortisol or prolactin in the animal models and early human pharmacodynamic studies in which it was tested. It is studied in research contexts involving modulation of the growth hormone axis, support for lean muscle mass, fat metabolism, and recovery physiology. Its defining feature is receptor selectivity compared with earlier growth hormone releasing peptides.

Ipamorelin is a ghrelin receptor (GHS-R1a) agonist that mimics ghrelin signaling and stimulates growth hormone release from pituitary somatotropes. GHS-R1a signaling is linked to phospholipase C activation and intracellular calcium mobilization, which contributes to GH secretion.

Unlike earlier GHRPs such as GHRP-2 and GHRP-6, Ipamorelin showed minimal ACTH and cortisol release in early pharmacodynamic studies, including the study by Raun et al., where this effect was observed even at doses far above the GH ED50 in the tested model. This relative endocrine selectivity is a key differentiator of Ipamorelin and is why it is often discussed in GH-axis research compared with older GHRPs.

This mechanism also differs fundamentally from GHRH analogues such as CJC-1295 and Sermorelin, which act through cAMP-mediated pathways at the GHRH receptor rather than the GHS-R1a receptor. Ipamorelin represents a distinct receptor class within GH axis modulation, and this difference has practical implications for how it is combined with GHRH-class peptides in research frameworks.

What Is Ipamorelin Used For?

Ipamorelin is primarily investigated in research settings to evaluate growth hormone modulation and downstream effects on IGF-1 signaling. These include lean muscle mass modeling, studies of adipose tissue metabolism, recovery physiology, and frameworks for age-related GH decline.

Mechanistically, Ipamorelin is a ghrelin receptor (GHS-R1a) agonist that stimulates pulsatile growth hormone release from the pituitary. GH then promotes hepatic IGF-1 production, making IGF-1 a major downstream mediator of GH signaling.

The GH–IGF-1 axis influences:

• Skeletal muscle protein synthesis
• Lipid mobilization and oxidation
• Connective tissue remodeling
• Systemic metabolic regulation

Importantly, Ipamorelin amplifies natural growth hormone production rather than replacing it, preserving endogenous circadian pulsatility. This is a key distinction compared with exogenous recombinant GH administration, which bypasses regulatory feedback loops. Practitioner-reported protocols sometimes align administration with nocturnal GH peaks, reflecting endogenous secretion physiology, though these patterns remain observational and not validated in controlled clinical trials.

Licensed professionals evaluating options to buy Ipamorelin online for research can contact Medica Depot’s support representatives for documentation guidance and sourcing support.

Ipamorelin Benefits: Lean Muscle Mass, Weight Loss & Recovery

Evidence supporting Ipamorelin’s physiological effects is primarily derived from preclinical studies, early-phase human pharmacodynamic trials, and practitioner-reported outcomes rather than large-scale RCTs.

Lean Muscle Mass

GH/IGF-1 signaling is associated with increased protein synthesis and satellite cell activation in skeletal muscle. Animal models of GHS-R activation demonstrate improvements in body composition and preservation of lean tissue, though translation to healthy human populations remains unconfirmed and should be framed as preclinical.

Weight Loss and Body Composition

Growth hormone enhances lipolysis and fatty acid mobilization, supporting theoretical applications in weight-loss and body-weight management research models. Ipamorelin-specific fat-reduction data in humans remain limited, and outcomes are inferred from class-level GH physiology rather than from compound-specific trials.

Many practitioners seek wholesale pricing when ordering Ipamorelin for research frameworks involving multiple sites or extended protocols.

Recovery and Tissue Repair

Practitioner reports suggest improved recovery kinetics, connective tissue support, and sleep quality, likely mediated via IGF-1-dependent collagen synthesis pathways. These effects are practitioner-reported and extrapolated from GH/IGF-1 biology, and remain unverified in controlled clinical endpoints.

For practitioners looking to buy research-grade Ipamorelin with verified purity, Medica Depot provides documentation guidance and sourcing support for licensed professionals.

How Ipamorelin Works & the Ipamorelin CJC-1295 Stack

Ipamorelin acts via selective agonism at GHS-R1a, triggering intracellular calcium mobilization and exocytosis of GH vesicles in pituitary somatotrophs. This produces a short-lived GH pulse that subsequently drives hepatic IGF-1 synthesis.

The selectivity advantage over earlier GHRPs is a key differentiator in Ipamorelin research. In the Raun et al. study, Ipamorelin showed minimal ACTH and cortisol activation compared with GHRP-2 and GHRP-6, while GH release remained robust in the tested model.

In combined research frameworks, Ipamorelin is often paired with the GHRH analogue CJC-1295. CJC-1295 prolongs GH pulse amplitude via GHRH receptor activation, while Ipamorelin initiates discrete secretory bursts via GHS-R1a. This dual-receptor mechanism produces additive GH release:

• CJC-1295: sustained GH potentiation
• Ipamorelin: pulse initiation

The combination is mechanistically complementary rather than competitive. When combined with CJC-1295, Ipamorelin timing is typically independent of the weekly CJC-1295 injection schedule due to their differing pharmacokinetic profiles.

Ipamorelin Dosage (Research Context Only)

Common practitioner-reported ranges include:

• Dose: 100 to 300 mcg subcutaneous injection
• Frequency: two to three times daily or pre-sleep administration
• Combination timing with CJC-1295: independent, due to differing pharmacokinetics

Reconstitution typically uses bacteriostatic water, with storage at 2 to 8°C post-reconstitution and protection from light. These practices are derived from research-use handling conventions and are not standardized clinical protocols.

When you order Ipamorelin, confirm storage requirements (2 to 8°C post-reconstitution) and light protection with your supplier to maintain research-grade integrity. When you buy Ipamorelin for research purposes, ensure the supplier provides certificate of analysis documentation and sterility controls before procurement.

All dosing information is practitioner-reported or research-extrapolated. No FDA-validated protocol exists for Ipamorelin.

Ipamorelin Side Effects

Ipamorelin is generally characterized by a favorable tolerability profile compared to older GHRPs.

Reported observations include:

• Mild injection site reactions
• Transient headache or flushing
• Mild water retention (IGF-1 mediated; extrapolated from GH class data)
• Nausea or fatigue in some observational contexts

More importantly, early human and animal studies indicate no significant elevation of cortisol or prolactin at GH-active doses, reinforcing its selective endocrine profile. However, long-term safety data in healthy populations are not established.

Theoretical risks associated with chronic GH/IGF-1 elevation, including metabolic, oncologic, and cardiovascular considerations, remain unresolved and should be clearly communicated in any research context.

Ipamorelin vs Sermorelin, CJC-1295 & Tesamorelin

• Versus Sermorelin: Ipamorelin is a GHS-R agonist, while Sermorelin is a GHRH analogue acting at the hypothalamic-pituitary GHRH receptor. These are different receptor classes with different GH release profiles. Sermorelin had historical FDA approval for pediatric GH deficiency that was subsequently withdrawn for commercial, not safety, reasons, whereas Ipamorelin remains a research compound. The practical research distinction lies in receptor-targeting preference and endocrine selectivity. Ipamorelin’s no-cortisol profile is not replicated by Sermorelin, which stimulates pituitary GH through a different axis.
• Versus CJC-1295: Ipamorelin and CJC-1295 are not competitors — they are mechanistically complementary. Ipamorelin initiates the GH pulse via GHS-R1a activation, while CJC-1295 prolongs GH release via GHRH receptor engagement. In research frameworks, the combination is the more common evaluation approach rather than choosing one over the other.
• Versus Tesamorelin: Tesamorelin is a GHRH analogue with FDA approval for HIV-associated lipodystrophy. Ipamorelin lacks any approved indication and is only in investigational research frameworks. The receptor class also differs; Tesamorelin acts at the GHRH receptor, while Ipamorelin acts at GHS-R1a. Research choice between the two depends on whether the goal is to study GHRH-axis stimulation or selective GHS-R-mediated pulsatile GH release.

Legal Status of Ipamorelin

Researchers evaluating Ipamorelin when buying online should review certificate of analysis documentation, sterility controls, storage requirements, and jurisdiction-specific regulatory status before any procurement decision. Research institutions assessing procurement options may also compare wholesale pricing structures when planning multi-site protocol evaluations.

• United States: Ipamorelin is not FDA-approved for any therapeutic indication. In September 2023, the FDA classified Ipamorelin as a Category 2 substance, prohibiting its use by 503A and 503B compounding pharmacies. In late 2024, Ipamorelin was removed from the Category 2 list and placed under PCAC review. The regulatory position on compounded Ipamorelin therefore remains unsettled; practitioners should verify current FDA compounding status directly before any procurement or protocol decision. Practicians evaluating where to buy Ipamorelin should verify current FDA compounding status directly before any procurement decision.
• Australia: Ipamorelin is not TGA-approved. Compounding availability is restricted under peptide regulations. Practitioners should verify current TGA status and local compounding requirements before evaluation or procurement.
• WADA: GH secretagogues, including Ipamorelin, are prohibited at all times under the WADA S2 category covering peptide hormones, growth factors, related substances, and mimetics. This prohibition applies both in competition and out of competition. Practitioners working with competitive athletes should communicate this prohibition clearly and advise independent verification of the most current WADA Prohibited List.

Regulatory information is current as of May 2026 and is subject to change. Practitioners should verify jurisdiction-specific regulations before evaluating or sourcing any Ipamorelin formulation.

Where Can Practitioners Buy Ipamorelin Online?

Ipamorelin is available for purchase online exclusively by qualified professionals evaluating this GH secretagogue for laboratory or investigational use. Given the evolving FDA compounding landscape for Ipamorelin, sourcing should be limited to suppliers that provide verifiable purity documentation, certificate of analysis, LOT number traceability, and jurisdiction-specific compliance records. Medica Depot provides documentation guidance and procurement support for qualified professionals evaluating research-grade GH-axis peptides.

Contact Medica Depot’s support representatives for guidance with sourcing documentation and to access available product references.

FAQs

1. What is Ipamorelin used for?

Ipamorelin is being investigated in research settings for GH release modulation, support for lean muscle mass, weight-loss modeling, and recovery physiology. It selectively stimulates GHS-R1a without significantly increasing cortisol or prolactin, distinguishing it from older GHRPs. All applications are research-based and should not be presented as validated clinical therapies.

2. What does Ipamorelin do?

It binds the ghrelin receptor (GHS-R1a) in the anterior pituitary to trigger pulsatile GH secretion, which increases downstream IGF-1 production from the liver. This pathway is associated with anabolic and metabolic signaling in preclinical models. Its defining feature is GH stimulation without corresponding elevations in cortisol or prolactin.

3. What is the Ipamorelin dosage?

Commonly reported research-use ranges are 100 to 300 mcg subcutaneously, administered two to three times daily or before sleep. When combined with CJC-1295, Ipamorelin’s timing is independent of the weekly injection schedule due to its distinct pharmacokinetics. All dosing is practitioner-reported and not clinically standardized.

4. What are Ipamorelin benefits?

Reported research-context benefits include lean muscle support through GH/IGF-1-mediated protein synthesis, fat metabolism effects via GH-induced lipolysis, and recovery enhancement. Sleep quality improvement is also practitioner-reported. Evidence is primarily preclinical and early human pharmacodynamic, and claims should reflect the available evidence tier.

5. What are Ipamorelin side effects?

Mild injection site reactions, transient headache, and mild water retention are most commonly reported. Importantly, cortisol and prolactin do not significantly increase at research doses, distinguishing Ipamorelin from older GHRPs. Long-term safety remains insufficiently characterized, and the theoretical risks of chronic GH/IGF-1 elevation should be communicated clearly.

6. Ipamorelin vs Sermorelin — what’s the difference?

Ipamorelin is a ghrelin receptor (GHS-R1a) agonist, while Sermorelin is a growth hormone-releasing hormone (GHRH) analogue, so they act through different receptors and can produce different GH release patterns. Sermorelin has a historical FDA approval, while Ipamorelin is not FDA-approved and is generally treated as a research-use compound in the U.S.

7. Is Ipamorelin legal?

Ipamorelin is not FDA-approved or TGA-approved. In the United States, it was classified as Category 2 under the FDA’s interim compounding policy in September 2023, prohibiting its use by compounding pharmacies. It is prohibited at all times under WADA S2, including out of competition, making it unsuitable for competitive athletes. Jurisdiction-specific rules vary and should be verified before evaluation or procurement.

Citations

1. Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of Ipamorelin, a growth hormone-releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402
2. Raun K, Hansen B, Johansen N, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. 1999;402(6762):656-660. doi:10.1038/45230
4. Ankersen M, Johansen NL, Madsen K, et al. A new series of highly potent growth hormone-releasing peptides derived from Ipamorelin. J Med Chem. 1998;41(19):3699-3704. doi:10.1021/jm9801962

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.